Dose Escalation Completed For Rise Therapeutics' R-3750 And R-2487 Clinical Trials
Date
1/6/2025 12:31:06 PM
(MENAFN- PR Newswire)
"The clinical transition of these programs into the expansion enrollment stage is an important milestone highlighting safety for both drugs," states Gary
Fanger President and CEO of Rise Therapeutics. "With the emergence of biomarker, pharmacodynamic, and clinical activity datasets from these studies, we are executing on our mission to validate our novel synthetic biology-based drug approach that harnesses natural immune regulatory mechanisms to correct disease early via convenient oral immunotherapy."
Dose Escalation Completed for Rise Therapeutics' R-3750 and R-2487 Clinical Trials
Post thi
R-2487 is being tested in a clinical trial designed to understand safety, pharmacodynamics, and clinical activity in patients suffering from rheumatoid arthritis (NCT05961592). R-3750 is being tested in a clinical trial designed to understand safety, pharmacodynamics, and clinical activity in patients suffering from ulcerative colitis (NCT05666960). Importantly, each clinical study is designed to identify novel biomarkers. The repeat dose studies are positioning these novel drugs to intervene early in disease progression prior to traditional infused biologics therapy affording an opportunity to correct disease prior to severe tissue damage.
About R-3750
Ulcerative colitis is a lifelong disease afflicting 5 million people worldwide, where the few available treatments can have risks and debilitating side effects. R-3750 represents a novel breakthrough to treating
this devastating disease and, as an immunologically-directed microbiome medication, reduces gut inflammation, improves intestinal barrier integrity, and directs a more normal microbiome make-up.
About R-2487
Rheumatoid arthritis is a chronic, systemic inflammatory disorder affecting up to 0.24% of the world population, and as much as 1% of the US population. R-2487 works by inducing evolution of specific immune cells called T regulatory (Treg) cells via a novel mechanism of action, resetting Treg deficiencies to reduce inflammatory cytokines that contribute to rheumatoid arthritis.
About Rise Therapeutics
Rise Therapeutics, a biotechnology company located in Rockville, Maryland, leverages its expertise in synthetic biology and immunological drug development to create novel cellular-based immune therapies. With a strong emphasis on product development and its internal clinical GMP manufacturing infrastructure, Rise is focused on developing immunological-based biological medicines using a unique and proprietary oral biologics delivery platform. For more information, go to .
Contact:
[email protected]
SOURCE Rise Therapeutics
MENAFN06012025003732001241ID1109059940
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.